Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza & Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and Others) With Forecast (2018-2023)

Report Code : HCR 0130 Format Type: PDF+ Excel Database

Antivirals are drugs that are used to treat viral infections. While a majority of antivirals are used for treating specific viral infections, there are a few broad-spectrum antivirals to treat other viral infections. As opposed to antibiotics that actually destroy the target pathogen, antivirals only inhibit the growth of the pathogen. Antivirals have the advantage of not causing any side effects and focus on inibiting the replication of the virus. An increase in the disease afflicted population across the globe is one of the major drivers for this market. Apart from this, increasing levels of awareness coupled with the launch of newer and more effective drugs, this market has tremendous opportunities in emerging economies. The antiviral market is expected to grow at a steady and healthy growth rate till the end of the forecast period considered in this report.  Expiry of patents is another factor providing opportunities for this market. Factors that include government policies can prove to be challenges in this market. 

The report also provides an exhaustive overview of antiviral research and development pipeline. A huge amount of research and development is underway to extend the range of antivirals to treat other pathogens. Also, with the tendency of viruses to mutate and become drug resistant, the need of the hour is to develop and refresh the pipeline of antivirals with new therapies.  A section on patent analysis is also included. 

Antivirals Market

Antiviral drugs are used in the treatment of  HIV, herpes viruses, the hepatitis B and C viruses, and influenza A and B viruses. The global antivirals market is expected to be dominated by HIV antivirals. According to the WHO and UNAIDS estimates, 36.7 million people were living with HIV globally at the end of 2015. In 2015, approximately 2.1 million people became newly infected and 1.1 million died of HIV-related causes. 

The Antivirals market can be segmented on the basis of type as:
  • HIV Antivirals
  • Hepatitis-C Antivirals
  • Herpes Antivirals
  • Influenza Antivirals
  • Hepatitis-B Antivirals
  • Other Antivirals 

In terms of actions, the Antivirals market has been segmented across the following:
  • DNA polymerase inhibitors
  • NS3 Protease inhibitors
  • Reverse transcriptase inhibitors 
The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

Sample Companies Profiled in this Report are: 
  • GlaxoSmithKline plc
  • Merck & Co
  • Johnson and Johnson
  • Novartis International AG
  • Gilead Sciences Inc
  • 10+


Request Sample Data